We found that most eosinophils were localized to the PVAT and not to actual lesion, indicating that eosinophils do not influence lesion development through actions within the plaque

We found that most eosinophils were localized to the PVAT and not to actual lesion, indicating that eosinophils do not influence lesion development through actions within the plaque. of IL-5 reversed the IL-2-complex-induced eosinophilia but did not switch lesion size. Conclusions This study demonstrates that growth of NU6027 CD25-expressing ILCs by IL-2/anti-IL-2 complexes prospects to a reduction in VLDL cholesterol and atherosclerosis. Global depletion of ILCs by anti-CD90.2 did not significantly affect lesion size indicating that different ILC subsets may have divergent effects on atherosclerosis. Keywords: Innate lymphoid cells, atherosclerosis, IL-5, eosinophils INTRODUCTION The development of atherosclerotic lesions and the destabilization of established lesions are promoted by local arterial and systemic inflammation driven by innate and adaptive immune responses. Interferon- (IFN-)-secreting TH1 cells enhance lesion development, but the influence of TH2 or TH17 cells is usually uncertain 1. Innate lymphoid cells (ILCs) have emerged as important effector cells in both protective immunity against pathogens and immune/inflammatory diseases 2, 3. Each subset of ILCs, type 1, 2 or 3 3, secretes a distinct group of cytokines. The pattern of cytokine production corresponds approximately to that of its T cell ETO counterpart: ILC1s secrete Th1-related cytokines, ILC2s secrete Th2-related cytokines and ILC3s secrete Th17-related cytokines. The influence of each of these ILC subsets to atherosclerosis is largely unknown. Natural killer (NK) cells, which are cytotoxic and IFN–secreting innate cells that are phenotypically related to the ILC1 subset, appear to promote atherosclerotic lesion development in mice 4. The contribution of non-cytotoxic interferon- secreting ILC1s has not been resolved. Group 2 ILCs secrete IL-4, IL-5, IL-9 and IL-13 in response to IL-25, IL-33 and TSLP. These cells play a role in metabolic homeostasis by reducing adiposity, a function mediated in part by IL-5-dependent eosinophil activation 5-7. As of yet, there is no ILC-specific knockout mouse collection that does not also have deficiencies in other lymphocyte populations 8. However, injections of NU6027 anti-CD90 antibodies selectively deplete NU6027 CD90-expressing ILCs in V-D-J recombinase-1 or ?2 (or mice selectively allows growth of CD25+ ILC2s 11. In immunocompetent mice, treatment of mice with IL-2/anti-IL-2 complexes expands regulatory T cells (Treg) 12, 13, and has been proposed as a therapeutic approach for autoimmunity, graft vs. host disease and allograft rejection 14. IL-2/anti-IL-2 complex therapy reduces atherosclerotic lesion development in mice 15, 16, but the effect of this therapy on ILC growth in atherosclerosis models in not known. In this study, we investigated the influence of ILCs on atherosclerotic lesion development. We used antibody-mediated global ILC depletion NU6027 and IL-2/anti-IL-2-driven growth in mice, which are atherosclerosis prone but lack adaptive immune cells. We show that IL-5-generating ILCs are present in atherosclerotic aortas. Global depletion of all CD90+ ILCs, which include the majority of all three groups of ILCs, prospects to a reduction in type 1, 2 and 3 cytokine production in the spleen, with no net effect on atherosclerotic lesion development. However, IL-2/anti-IL-2 treatment results in a marked increase in ILC2s, eosinophilia, reduced VLDL cholesterol levels and protection against atherosclerotic lesion development. The results spotlight the potential role of therapeutic growth of type 2 ILCs for the treatment of atherosclerotic vascular disease. MATERIALS AND METHODS Materials and NU6027 Methods are available in the online-only Data Product RESULTS Aortic CD90+CD127+CD25+ innate lymphoid cells produce type 2 cytokines First we tested if hypercholesterolemia would influence levels of ILCs in the aorta. Mice were fed either high-fat diet (HFD) or chow diet for 10 weeks where after the aorta was digested and.